Which has higher earnings and valuation, MNPR or ONCY?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is MNPR or ONCY more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Oncolytics Biotech N/A -2,185.97% -321.54%

Which has higher earnings & valuation, ONCY or ANL?

Oncolytics Biotech has higher earnings, but lower revenue than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A Adlai Nortye $5M 82.56 -$35.53M N/A N/A

Is ONCY or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -321.54% Adlai Nortye N/A N/A N/A

Which has higher earnings and valuation, ONCY or EPRX?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A

Is ONCY or EPRX more profitable?

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -321.54% Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Which has higher earnings and valuation, IPSC or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Century Therapeutics N/A N/A -$9.58M -$1.14 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is IPSC or ONCY more profitable?

Century Therapeutics' return on equity of -49.89% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% Oncolytics Biotech N/A -2,185.97% -321.54%

Oncolytics Biotech (ONCY) Competitors

$0.80 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.49%)

As of 06/12/2026 07:57 PM Eastern

Compare

ONCY vs. MNPR, ANL, EPRX, IPSC, and UPB

Should you buy Oncolytics Biotech stock or one of its competitors? MarketBeat compares Oncolytics Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncolytics Biotech include Monopar Therapeutics (MNPR), Adlai Nortye (ANL), Eupraxia Pharmaceuticals (EPRX), Century Therapeutics (IPSC), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

How does Oncolytics Biotech compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Monopar Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 2 mentions for Monopar Therapeutics and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Monopar Therapeutics' score of 0.41 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Monopar Therapeutics	Neutral
Oncolytics Biotech	Very Positive

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Monopar Therapeutics currently has a consensus price target of $107.91, suggesting a potential upside of 80.54%. Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 958.53%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Monopar Therapeutics' return on equity of -12.84% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Summary

Monopar Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Adlai Nortye?

Oncolytics Biotech (NASDAQ:ONCY) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, Oncolytics Biotech and Oncolytics Biotech both had 1 articles in the media. Oncolytics Biotech's average media sentiment score of 1.89 beat Adlai Nortye's score of 1.87 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Oncolytics Biotech	Very Positive
Adlai Nortye	Very Positive

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oncolytics Biotech has higher earnings, but lower revenue than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Adlai Nortye	$5M	82.56	-$35.53M	N/A	N/A

Oncolytics Biotech has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Oncolytics Biotech presently has a consensus target price of $8.50, indicating a potential upside of 958.53%. Adlai Nortye has a consensus target price of $24.25, indicating a potential upside of 134.98%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Adlai Nortye's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Adlai Nortye	N/A	N/A	N/A

Summary

Oncolytics Biotech beats Adlai Nortye on 7 of the 12 factors compared between the two stocks.

How does Oncolytics Biotech compare to Eupraxia Pharmaceuticals?

Oncolytics Biotech (NASDAQ:ONCY) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Oncolytics Biotech has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Eupraxia Pharmaceuticals' score of 0.62 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Oncolytics Biotech	Very Positive
Eupraxia Pharmaceuticals	Positive

Oncolytics Biotech currently has a consensus target price of $8.50, suggesting a potential upside of 958.53%. Eupraxia Pharmaceuticals has a consensus target price of $18.33, suggesting a potential upside of 203.53%. Given Oncolytics Biotech's higher probable upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

6.8% of Oncolytics Biotech shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Oncolytics Biotech beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Century Therapeutics' return on equity of -49.89% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	N/A	N/A	-$9.58M	-$1.14	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, Century Therapeutics had 5 more articles in the media than Oncolytics Biotech. MarketBeat recorded 6 mentions for Century Therapeutics and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Century Therapeutics' score of 0.26 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Century Therapeutics	Neutral
Oncolytics Biotech	Very Positive

Century Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 111.11%. Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 958.53%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Summary

Century Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Upstream Bio currently has a consensus target price of $33.17, indicating a potential upside of 443.72%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 958.53%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oncolytics Biotech has lower revenue, but higher earnings than Upstream Bio. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	116.48	-$143.44M	-$2.91	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Upstream Bio has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Oncolytics Biotech has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

In the previous week, Upstream Bio had 9 more articles in the media than Oncolytics Biotech. MarketBeat recorded 10 mentions for Upstream Bio and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 1.89 beat Upstream Bio's score of 0.28 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Oncolytics Biotech	Very Positive

6.8% of Oncolytics Biotech shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Upstream Bio and Oncolytics Biotech tied by winning 8 of the 16 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$95.84M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.59	20.00	24.00	24.42
Price / Sales	N/A	304.30	514.65	112.54
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-20.08	8.32	10.69	6.82
Net Income	-$28.76M	$23.94M	$3.57B	$337.56M
7 Day Performance	-4.40%	1.84%	0.61%	1.16%
1 Month Performance	-5.53%	-0.04%	1.56%	3.16%
1 Year Performance	32.07%	44.82%	25.44%	30.60%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	2.4255 of 5 stars	$0.80 flat	$8.50 +958.5%	+32.1%	$95.84M	N/A	N/A	30	Positive News Gap Up
MNPR Monopar Therapeutics	2.0244 of 5 stars	$60.61 +1.9%	$107.91 +78.0%	+78.3%	$398.46M	N/A	N/A	10	News Coverage Analyst Downgrade
ANL Adlai Nortye	2.1946 of 5 stars	$10.23 +2.8%	$24.25 +137.0%	+512.5%	$398M	$5M	N/A	127	Gap Up
EPRX Eupraxia Pharmaceuticals	2.2375 of 5 stars	$5.99 +0.7%	$18.33 +206.1%	+56.5%	$386.86M	N/A	N/A	29	News Coverage Positive News
IPSC Century Therapeutics	2.0994 of 5 stars	$2.12 -0.5%	$4.75 +124.1%	+291.0%	$384.16M	N/A	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. MNPR, ANL, EPRX, IPSC, and UPB

How does Oncolytics Biotech compare to Monopar Therapeutics?

Summary

How does Oncolytics Biotech compare to Adlai Nortye?

Summary

How does Oncolytics Biotech compare to Eupraxia Pharmaceuticals?

Summary

How does Oncolytics Biotech compare to Century Therapeutics?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. MNPR, ANL, EPRX, IPSC, and UPB

How does Oncolytics Biotech compare to Monopar Therapeutics?

Which has more volatility & risk, MNPR or ONCY?

Do institutionals and insiders believe in MNPR or ONCY?

Does the media prefer MNPR or ONCY?

Which has higher earnings and valuation, MNPR or ONCY?

Do analysts prefer MNPR or ONCY?

Is MNPR or ONCY more profitable?

Summary

How does Oncolytics Biotech compare to Adlai Nortye?

Does the media refer more to ONCY or ANL?

Do institutionals and insiders believe in ONCY or ANL?

Which has higher earnings & valuation, ONCY or ANL?

Which has more volatility and risk, ONCY or ANL?

Do analysts recommend ONCY or ANL?

Is ONCY or ANL more profitable?

Summary

How does Oncolytics Biotech compare to Eupraxia Pharmaceuticals?

Which has higher earnings and valuation, ONCY or EPRX?

Is ONCY or EPRX more profitable?

Which has more risk and volatility, ONCY or EPRX?

Does the media favor ONCY or EPRX?

Do analysts prefer ONCY or EPRX?

Do institutionals and insiders believe in ONCY or EPRX?

Summary

How does Oncolytics Biotech compare to Century Therapeutics?

Is IPSC or ONCY more profitable?

Which has higher earnings and valuation, IPSC or ONCY?

Does the media refer more to IPSC or ONCY?

Do analysts prefer IPSC or ONCY?

Do institutionals & insiders hold more shares of IPSC or ONCY?

Which has more risk & volatility, IPSC or ONCY?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Do analysts rate UPB or ONCY?

Which has higher earnings and valuation, UPB or ONCY?

Which has more risk & volatility, UPB or ONCY?

Is UPB or ONCY more profitable?

Does the media refer more to UPB or ONCY?

Do insiders & institutionals believe in UPB or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools